10-Q: Surgery Partners Reports Q2 2026 Results: Net Loss Widens

Surgery Partners, Inc. announced its second quarter 2026 financial results, reporting a net loss attributable to the company of $15.0 million, a wider loss compared to the prior year's $2.5 million, alongside a 2.7% increase in total revenues.

Summary

• For the second quarter of 2026, Surgery Partners, Inc. reported total revenues of $848.9 million, an increase of 2.7% compared to $826.2 million in the same period of 2025.
• The company experienced a net loss attributable to Surgery Partners, Inc. of $15.0 million for Q2 2026, a significant increase from the $2.5 million net loss in Q2 2025.
• Adjusted EBITDA for Q2 2026 decreased by 2.9% to $125.2 million, down from $129.0 million in Q2 2025.
• Same-facility revenues for Q2 2026 increased by 5.0% year-over-year, driven by a 4.8% increase in revenue per case and a 0.3% increase in same-facility case volumes.
• For the six months ended June 30, 2026, total revenues were $1,659.8 million, up 3.6% from $1,602.2 million in the prior year period.
• The net loss attributable to Surgery Partners, Inc. for the first six months of 2026 was $50.9 million, compared to $40.2 million for the same period in 2025.
• Cash and cash equivalents stood at $216.7 million as of June 30, 2026.
• The company announced definitive agreements in July 2026 to sell its controlling interest in two hospitals for approximately $795 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the reported net loss attributable to Surgery Partners, Inc. and a decrease in Adjusted EBITDA, despite revenue growth.

Positives

• Total revenues increased by 2.7% to $848.9 million in Q2 2026 compared to $826.2 million in Q2 2025.
• Same-facility revenues grew by 5.0% in Q2 2026, indicating improved performance at existing facilities.
• Same-facility revenue per case increased by 4.8% in Q2 2026.
• Total revenues for the first six months of 2026 increased by 3.6% to $1,659.8 million.
• The company has a strong liquidity position with $216.7 million in cash and cash equivalents as of June 30, 2026.
• There is $617.8 million of borrowing capacity available under the senior secured revolving credit facility as of June 30, 2026.

Negatives

• Net loss attributable to Surgery Partners, Inc. widened significantly to $15.0 million in Q2 2026 from $2.5 million in Q2 2025.
• Adjusted EBITDA decreased by 2.9% to $125.2 million in Q2 2026 from $129.0 million in Q2 2025.
• Cost of revenues as a percentage of total revenues increased to 77.6% in Q2 2026 from 76.3% in Q2 2025.
• Net loss attributable to Surgery Partners, Inc. for the first six months of 2026 was $50.9 million, compared to $40.2 million in the prior year.
• Cash flows from operating activities decreased to $71.0 million for the first six months of 2026 from $87.3 million in the same period of 2025.
• Interest expense, net increased to $69.8 million in Q2 2026 from $67.9 million in Q2 2025.

Risks

• The potential sale transaction of ownership interests in Mountain View Hospital and Idaho Falls Community Hospital may not be completed in a timely manner or at all.
• Failure to satisfy other closing conditions to the sale transaction could prevent its completion.
• The anticipated benefits of the hospital sale may not be realized as expected.
• The announcement or pendency of the transaction could adversely affect business relationships and operating results.
• Reductions in payments from government health care programs and private insurance payors could impact revenues.
• Failure to maintain or develop relationships with physicians on beneficial terms could negatively affect operations.
• Supply chain issues, including shortages or quality control problems with surgery-related products, could arise.
• Cybersecurity attacks or intrusions could disrupt operations and compromise data.

Future Outlook

The company continues to focus on improving same-facility performance, selectively acquiring established facilities, developing new facilities, and pursuing other portfolio management initiatives. Management believes that cash flows from operations, available cash, available capacity on its Revolver, and anticipated continued access to capital markets will be adequate to meet short-term and long-term liquidity needs.

Management Comments

• We continue to focus on improving our same-facility performance, selectively acquiring established facilities, developing new facilities and pursuing other portfolio management initiatives.
• We had cash and cash equivalents of $216.7 million and $617.8 million of borrowing capacity under the Revolver as of June 30, 2026.
• Based on our current level of operations, we believe cash flows from operations, available cash, available capacity on our Revolver and continued anticipated access to capital markets, will be adequate to meet our short-term (i.e., 12 months) and long-term (beyond 12 months) liquidity needs.

Industry Context

StockSavvy.ai notes that Surgery Partners operates in the highly competitive healthcare services sector, specifically focusing on ambulatory surgery centers and surgical hospitals. The reported revenue growth, driven by same-facility performance, is a positive indicator in an industry facing evolving reimbursement landscapes and increasing demand for outpatient procedures. However, the widening net loss and decreased Adjusted EBITDA highlight the ongoing challenges in managing costs and profitability within this sector.

Comparison to Industry Standards

• The reported revenue growth of 2.7% for Q2 2026 is moderate compared to the overall healthcare services industry, which can vary significantly by sub-sector.
• The increase in same-facility revenue per case by 4.8% suggests effective pricing strategies or a shift towards higher-margin procedures, which is generally a positive trend across the industry.
• The widening net loss is a concern, as many healthcare providers are striving for profitability amidst rising operational costs and reimbursement pressures.
• The company's Adjusted EBITDA margin, while not explicitly stated, would be a key metric to compare against peers like Tenet Healthcare (THC) or HCA Healthcare (HCA), which operate in similar but broader segments of the healthcare market.

Legal Proceedings

• The company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices, and personal injuries.
• Management is not aware of any proceedings that are reasonably possible to have a material adverse effect on the company's business, financial position, results of operations, or liquidity.

Stakeholder Impact

• Shareholders may be concerned by the widening net loss and decreased Adjusted EBITDA, potentially impacting stock valuation.
• Employees may be affected by the ongoing focus on operational efficiency and potential integration of acquisitions or divestitures.
• Physicians, as partners and key stakeholders, are crucial to the company's success; maintaining beneficial relationships is highlighted as a focus.
• Creditors may note the company's debt levels and the impact of interest expenses on financial performance.

Next Steps

• Complete the definitive agreements to sell controlling interest in two hospitals for approximately $795 million, subject to customary closing conditions and approvals.
• Continue to focus on improving same-facility performance.
• Selectively acquire established facilities.
• Develop new facilities.
• Pursue other portfolio management initiatives.

Key Dates

Recommendation

While revenue growth and same-facility performance show positive signs, the widening net loss and decreased Adjusted EBITDA are significant concerns. The company's liquidity position is adequate, and the planned divestiture of two hospitals could improve financial flexibility. However, the current financial performance suggests a cautious approach, warranting a 'hold' recommendation until profitability improves and the impact of the divestiture is clearer.

Keywords

Surgery Partners, Ambulatory Surgery Centers, Surgical Hospitals, Healthcare Services, Revenue Growth, Net Loss, Adjusted EBITDA, Financial Results